Brief: Pulse Biosciences Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation
08/07/2024 13:22
July 8 (Reuters) - Pulse Biosciences Inc PLSE.O :
* PULSE BIOSCIENCES, INC. ANNOUNCES RECEIPT OF FDA
BREAKTHROUGH
DEVICE DESIGNATION FOR CELLFX® NSPFA CARDIAC SURGERY SYSTEM FOR
THE TREATMENT OF ATRIAL FIBRILLATION
* PULSE BIOSCIENCES INC - TO BEGIN PIVOTAL CLINICAL TRIAL
FOR AF
IN 2025
Source text for Eikon: ID:nBw6K6lgYa
Further company coverage: PLSE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pulse Biosciences
See all newsUS RESEARCH ROUNDUP-Affiliated Managers Group, Goldman Sachs, Vaxcyte
Pulse Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Pulse Biosciences Q2 net loss widens, cash position strengthens
Pulse Biosciences Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Pulse Biosciences, Inc. Announces Planned Redemption Of Warrants